Pill Identifier App

Inovio Biomedical DNA Delivery Technology Presented by Wyeth Researcher at Vaccine Conference

SAN DIEGO--(BUSINESS WIRE)--Feb 16, 2007 - Inovio Biomedical Corp. (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its development partner Wyeth (NYSE:WYE) presented preliminary scientific data on an investigational DNA vaccine for HIV, including results from a non-human primate study, using one of Inovio's proprietary DNA delivery systems. This presentation took place at the Vaccines - Linking Vaccine Development with Market Opportunities conference held in Brussels, Belgium, February 15 - 16, 2007.

Inovio's partnership and non-exclusive license agreement with Wyeth was announced in November 2006.

About Inovio's DNA Delivery Technology

DNA vaccines have the potential to by-pass scientific obstacles inherent in the development of conventional vaccines. For example, DNA vaccines may be better in stimulating cellular immunity necessary to fight chronic infection or diseases such as cancer. Despite this promise, vaccination using DNA plasmid alone, without enhanced delivery, has not been shown to reach the threshold for clinical benefit.

Intramuscular delivery of DNA vaccines using Inovio's proprietary electroporation technology has been shown in primate studies to boost the immune response by orders of magnitude over DNA plasmid alone. Plasmid-based vaccines induced higher levels of antibodies and T-cell responses when delivered via electroporation, suggesting the potential to provide better protection from infectious diseases such as HIV and hepatitis C.

About Inovio Biomedical Corporation

Inovio Biomedical Corporation is focused on commercializing its Selective Electrochemical Tumor Ablation (SECTA) therapy and development of multiple DNA vaccines using its delivery platform for gene-based treatments. SECTA is a local ablation therapy for solid tumors that is designed to selectively kill cancerous cells and minimize cosmetic or functional impacts to predominantly healthy tissue typically treated around the tumor. Inovio is moving its lead product, the MedPulser(R), through pre-marketing studies for head and neck cancer and skin cancers in Europe, where it has CE Mark accreditation, a U.S. phase III pivotal study for head and neck cancer, and a phase I/II trial for breast cancer. Inovio's DNA delivery partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, and the U.S. Army, with four gene-based therapies and DNA vaccines in phase I clinical studies. Inovio is a leader in developing human therapeutic applications of electroporation, which uses brief, controlled electrical pulses to dramatically increase cellular uptake of a useful biopharmaceutical, with the industry's most extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical results referenced in this release may not be indicative of results achievable from testing in humans), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of Inovio's technology as a delivery mechanism, the availability or potential availability of alternative therapies or treatments for the conditions targeted by Inovio or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether Inovio can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, and other factors set forth in the our Annual Report on Form 10-K for the year ended December 31, 2005, our Form 10-Q for the nine months ended September 30, 2006, and other regulatory filings. There can be no assurance that any product in our product pipeline will be successfully developed or manufactured, or that final results of clinical studies will be supportive of regulatory approvals required to market licensed products.

Contact

Inovio Biomedical Corporation
Investor Relations
Bernie Hertel, 858-410-3101
or
Media Relations
Jeff Richardson, 805-491-8313

Posted: February 2007

View comments

Hide
(web1)